Q2 EPS Estimate for PROCEPT BioRobotics Boosted by Analyst

PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for shares of PROCEPT BioRobotics in a note issued to investors on Monday, July 14th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn ($0.42) per share for the quarter, up from their prior forecast of ($0.43). The consensus estimate for PROCEPT BioRobotics' current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics' FY2025 earnings at ($1.53) EPS, FY2026 earnings at ($1.15) EPS and FY2028 earnings at ($0.22) EPS.

Other equities research analysts have also issued research reports about the stock. Wall Street Zen lowered shares of PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a research note on Saturday. Morgan Stanley decreased their price target on PROCEPT BioRobotics from $71.00 to $68.00 and set an "overweight" rating for the company in a research report on Tuesday. Oppenheimer assumed coverage on PROCEPT BioRobotics in a research report on Monday, July 7th. They set a "market perform" rating for the company. Stephens assumed coverage on PROCEPT BioRobotics in a research report on Wednesday, July 9th. They set an "overweight" rating and a $70.00 price target for the company. Finally, Truist Financial decreased their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $84.13.

PROCEPT BioRobotics Stock Down 1.7%

Shares of PRCT stock traded down $0.97 on Wednesday, hitting $57.04. The stock had a trading volume of 935,162 shares, compared to its average volume of 850,396. The business has a 50 day moving average of $58.54 and a 200 day moving average of $62.37. The stock has a market cap of $3.16 billion, a price-to-earnings ratio of -33.55 and a beta of 1.07. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.95 and a quick ratio of 7.75. PROCEPT BioRobotics has a 12-month low of $47.04 and a 12-month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The business had revenue of $69.16 million during the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 28.09% and a negative net margin of 36.20%. PROCEPT BioRobotics's quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.51) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Signaturefd LLC grew its position in PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after buying an additional 145 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in shares of PROCEPT BioRobotics by 1.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 14,165 shares of the company's stock worth $1,141,000 after purchasing an additional 150 shares in the last quarter. Amundi grew its holdings in shares of PROCEPT BioRobotics by 0.9% during the fourth quarter. Amundi now owns 20,143 shares of the company's stock worth $1,742,000 after purchasing an additional 183 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of PROCEPT BioRobotics by 32.5% during the first quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company's stock worth $64,000 after purchasing an additional 270 shares in the last quarter. Finally, CWM LLC grew its holdings in shares of PROCEPT BioRobotics by 69.5% during the first quarter. CWM LLC now owns 873 shares of the company's stock worth $51,000 after purchasing an additional 358 shares in the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $61.49, for a total value of $1,537,250.00. Following the completion of the sale, the director owned 14,363 shares of the company's stock, valued at approximately $883,180.87. This trade represents a 63.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold 100,000 shares of company stock valued at $6,271,250 over the last three months. Company insiders own 17.40% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).